| Literature DB >> 35208834 |
Liča Lozica1, Kasper Rømer Villumsen2, Ganwu Li3,4, Xiao Hu4, Maja Maurić Maljković5, Željko Gottstein1.
Abstract
Escherichia coli is the main bacterial cause of major economic losses and animal welfare issues in poultry production. In this study, we investigate the effect of an autogenous vaccine on E. coli strains longitudinally isolated from broiler breeder flocks on two farms. In total, 115 E. coli isolates were sequenced using Illumina technologies, and compared based on a single-nucleotide polymorphism (SNP) analysis of the core-genome and antimicrobial resistance (AMR) genes they carried. The results showed that SNP-based phylogeny corresponds to a previous multilocus-sequence typing (MLST)-based phylogeny. Highly virulent sequence types (STs), including ST117-F, ST95-B2, ST131-B2 and ST390-B2, showed a higher level of homogeneity. On the other hand, less frequent STs, such as ST1485, ST3232, ST7013 and ST8573, were phylogenetically more distant and carried a higher number of antimicrobial resistance genes in most cases. In total, 25 antimicrobial genes were detected, of which the most prevalent were mdf(A) (100%), sitABCD (71.3%) and tet(A) (13.91%). The frequency of AMR genes showed a decreasing trend over time in both farms. The highest prevalence was detected in strains belonging to the B1 phylogenetic group, confirming the previous notion that commensal strains act as reservoirs and carry more resistance genes than pathogenic strains that are mostly associated with virulence genes.Entities:
Keywords: AMR; Escherichia coli; SNP; autogenous vaccine; colibacillosis; poultry; whole-genome sequencing
Year: 2022 PMID: 35208834 PMCID: PMC8879504 DOI: 10.3390/microorganisms10020377
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Description of E. coli vaccination programs and antimicrobial treatment data (rearing and production period) for each flock in this study 1.
| Farm | Flock | Number of Analysed Strains per Flock | Vaccination | Age at the Time of Vaccination | Treatment |
|---|---|---|---|---|---|
|
| 1 | 10 | Commercial vaccines | 0 d | Doxycycline |
| 2 | 14 | Autogenous vaccine 2x | 10 w | Doxycycline, tiamulin | |
| 3 | 13 | Autogenous vaccine 2x | 12 w | - | |
| 4 | 14 | Autogenous vaccine 2x | 10 w | Amoxicillin, doxycycline, enrofloxacin, oxytetracycline | |
|
| 1 | 13 | Commercial vaccines | 0 d | Doxycycline, enrofloxacin, tylosin |
| 2 | 7 | Commercial vaccines | 0 d | Amoxicilllin, polymyxin E, tylosin | |
| 3 | 15 | Autogenous vaccine 2x | 9 w | Doxycycline, polymyxin E | |
| 4 | 16 | Autogenous vaccine 2x | 10 w | Doxycycline, enrofloxacin | |
| 5 | 13 | Autogenous vaccine 2x | 9 w | Amoxicillin, enrofloxacin |
1 adapted from Lozica et al., 2021.
Figure 1SNP-based phylogenetic tree showing distribution of AMR genes among 115 E. coli sequences. The analysis includes 19 reference E. coli genomes representing different STs and phylogenetic groups.
Prevalence of the identified acquired AMR genes (n (%)).
| AMR Gene | Phenotype | Number of AMR Genes on Farm A * | Number of AMR Genes on Farm B ** | Total Number of AMR Genes |
|---|---|---|---|---|
|
| apramycin, gentamicin, tobramycin, dibekacin, netilmicin, sisomicin | 1 (1.96) | 0 | 1 (0.87) |
|
| gentamicin | 1 (1.96) | 0 | 1 (0.87) |
|
| spectinomycin | 2 (3.92) | 0 | 2 (1.74) |
|
| spectinomycin, streptomycin | 1 (1.96) | 0 | 1 (0.87) |
|
| streptomycin | 5 (9.8) | 0 | 5 (4.35) |
|
| streptomycin | 5 (9.81) | 0 | 5 (4.35) |
|
| amoxicillin, amoxicillin + clavulanic acid, ampicillin, ampicillin + clavulanic acid, cefotaxime, cefotxitin, ceftazidime, piperacillin, piperacillin + tazobactam, ticarcillin, ticarcillin + clavulanic acid | 1 (1.96) | 0 | 1 (0.87) |
|
| amoxicillin, ampicillin, cephalothin, piperacillin, ticarcillin | 3 (5.88) | 0 | 3 (2.61) |
|
| amoxicillin, ampicillin, cephalothin, piperacillin, ticarcillin | 4 (7.84) | 0 | 4 (3.48) |
|
| amoxicillin, ampicillin, cephalothin, piperacillin, ticarcillin | 2 (3.92) | 0 | 2 (1.74) |
|
| amoxicillin, amoxicillin + clavulanic acid, ampicillin, ampicillin + clavulanic acid, piperacillin, piperacillin + tazobactam, ticarcillin, ticarcillin + clavulanic acid | 2 (3.92) | 0 | 2 (1.74) |
|
| unknown beta-lactam | 3 (5.88) | 0 | 3 (2.61) |
|
| chloramphenicol | 1 (1.96) | 0 | 1 (0.87) |
|
| chloramphenicol | 1 (1.96) | 0 | 1 (0.87) |
|
| trimethoprim | 2 (3.92) | 1 (1.56) | 3 (2.61) |
|
| trimethoprim | 1 (1.96) | 0 | 1 (0.87) |
|
| unknown macrolide, aminoglycoside, tetracycline, fluoroquinolone, phenicol and rifamycin | 51 (100) | 64 (100) | 115 (100) |
|
| benzylkonium chloride, ethidium bromide, chlorhexidine, cetylpyridinium | 1 (1.96) | 0 | 1 (0.87) |
|
| ciprofloxacin | 2 (3.92) | 0 | 2 (1.74) |
|
| hydrogen peroxide | 31 (60.78) | 51 (79.69) | 82 (71.3) |
|
| sulfamethoxazole | 1 (1.96) | 0 | 1 (0.87) |
|
| sulfamethoxazole | 3 (5.88) | 2 (3.13) | 5 (4.35) |
|
| sulfamethoxazole | 1 (1.96) | 0 | 1 (0.87) |
|
| doxycycline, tetracycline | 17 (33.33) | 0 | 17 (14.78) |
|
| doxycycline, tetracycline, minocycline | 2 (3.92) | 2 (3.13) | 4 (3.48) |
*, ** Statistically significant difference in AMR gene frequency was detected between the farms (p ≤ 0.01).
Figure 2AMR gene frequency per flock on each farm (A) and per each detected phylogenetic group (B).